ReviewInflammopharmacology2022
COVID-19 and corticosteroids: a narrative review.
Review in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.International journal of molecular sciences · 2024Pooled it
- Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.Annals of medicine · 2022Pooled it
- Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.Nature communications · 2026Article
- Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets.Viruses · 2026Review
- The SARS-CoV-2 nucleocapsid protein induces microglia senescence-mediated cognitive impairment via Glycolysis.Molecular medicine (Cambridge, Mass.) · 2025Article
- Autologous bone marrow mononuclear cell transplantation for osteonecrosis of the femoral head in post-covid-19 syndrome: A case series.Regenerative therapy · 2025Article
- Association between 25(OH)D levels and clinical outcomes in patients infected with SARS-CoV-2: a cross-sectional study.Scientific reports · 2025Article
- Association Between Nursing Diagnoses and Mortality in Hospitalized Patients with COVID-19: A Retrospective Cohort Study.Nursing reports (Pavia, Italy) · 2025Article
- Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation.International journal of molecular sciences · 2025Review
- The Possible Role of Metformin and Fibroblast Growth Factor-21 in Multiple Sclerosis Neuropathology: Birds of a Feather Flock Together.The European journal of neuroscience · 2025Review
- Predictors of venous thromboembolic events in hospitalized patients with COVID-19.Journal of thrombosis and thrombolysis · 2025Article
- Evaluation of candidemia cases in the intensive care unit of a tertiary training hospital during the period of COVID-19 pandemic.BMC infectious diseases · 2025Article
- Association between COVID-19 Mortality and Underlying Disease; Tehran, Iran.Journal of caring sciences · 2025Review
- Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach.Pharmaceutics · 2025Review
- Autophagy modulators in type 2 diabetes: A new perspective.Journal of diabetes · 2024Review
- Lipid-Polymer Hybrid Nanoparticles in Microparticle-Based Powder: Evaluating the Potential of Methylprednisolone Delivery for Future Lung Disease Treatment via Inhalation.Pharmaceutics · 2024Article
- Opportunity for severe and critical COVID-19 pneumonia treatment with corticosteroids: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Review
- Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model.Scientific reports · 2024Article
- Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that corticosteroid therapy was effective in the management of severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), and recently in coronavirus disease 2019 (COVID-19). Corticosteroids are potent anti-inflammatory drugs that mitigate the risk of acute respiratory distress syndrome (ARDS) in COVID-19 and other viral pneumonia, despite a reduction of viral clearance; corticosteroids inhibit the development of cytokine storm and multi-organ damage. The risk-benefit ratio should be assessed for critical COVID-19 patients. In conclusion, corticosteroid therapy is an effective way in the management of COVID-19, it reduces the risk of complications primarily acute lung injury and the development of ARDS. Besides, corticosteroid therapy mainly dexamethasone and methylprednisolone are effective in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, and inflammatory bowel disease (IBD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.